FDA expands Bayer lung cancer drug approval

The FDA has expanded approval for Bayer's lung cancer drug, broadening its indicated patient population. The move follows clinical data supporting the expansion, though specific trial details and patient subgroups are not provided. This is a regulatory milestone for Bayer, potentially expanding its market reach in oncology.